Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Heparin-induced thrombocytopenia.

F Fabris1, G Luzzatto, P M Stefani

  • 1Istituto di Semeiotica Medica, via Ospedale 105, 35100 Padua, Italy. ffabris@ux1.unipd.it.

Haematologica
|January 12, 2000
PubMed
Summary

Heparin-induced thrombocytopenia (HIT) type II is an immune complication of heparin therapy, potentially causing dangerous thrombosis. Early diagnosis and prompt cessation of heparin, along with alternative anticoagulation, are crucial for patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antiplatelet glycoprotein autoantibodies in patients with autoimmune diseases with and without thrombocytopenia.

Journal of clinical immunology·1996
Same author

Unexpected low prevalence of FVIII gene inversion in severe hemophilia A patients from north-eastern Italy.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·1996
Same author

Compound heterozygous protein C deficiency resulting in the presence of only the beta-form of protein C in plasma.

Blood·1996
Same author

Inhibitory effect of prostacyclin and nitroprusside on type IIB von Willebrand factor-promoted platelet activation.

Thrombosis and haemostasis·1996
Same author

Homozygous patients with APC resistance may remain paucisymptomatic or asymptomatic during oral contraception.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·1996
Same author

Deep venous thrombosis and lupus anticoagulant. A case-control study.

Thrombosis and haemostasis·1996

Area of Science:

  • Immunology
  • Hematology
  • Pharmacology

Background:

  • Heparin-induced thrombocytopenia (HIT) type II is a dangerous immune complication of heparin therapy, characterized by significant thrombocytopenia and potential thrombosis.
  • HIT II affects approximately 2% of patients on unfractionated heparin, with lower incidence in those on low molecular weight heparin.
  • The condition arises from an immune response to heparin-PF4 complexes, activating platelets and leading to endothelial damage.

Purpose of the Study:

  • To review recent advances in understanding heparin-induced thrombocytopenia type II.
  • To provide critical guidelines for the clinical diagnosis and management of HIT II.
  • To highlight the diagnostic challenges and treatment strategies for HIT II.

Main Methods:

Related Experiment Videos

  • Review of current literature on heparin-induced thrombocytopenia type II.
  • Analysis of diagnostic criteria, including clinical presentation and laboratory tests (ELISA, platelet aggregation).
  • Evaluation of treatment options, including heparin cessation and alternative anticoagulants.

    • Main Results:

    • HIT II diagnosis relies on clinical suspicion and laboratory confirmation of heparin-dependent antibodies.
    • Thrombotic complications occur in 30% of HIT II patients, with a 20% mortality rate.
    • Immediate cessation of heparin and initiation of alternative anticoagulation (e.g., LMWH, direct thrombin inhibitors) are recommended.

    Conclusions:

    • Further research is needed to fully elucidate HIT II pathogenesis and identify factors predicting thrombotic complications.
    • Optimal therapeutic strategies for HIT II require validation in larger clinical trials.
    • Accurate diagnosis and prompt management are essential to mitigate the risks associated with HIT II.